Disease · EFO_0009104

hyperuricemia

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. hyperuricemia. Diseases, record EFO_0009104. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/EFO_0009104

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: hyperuricemia
Open Targets ID: EFO_0009104
Other names: Elevated uric acid concentration, Elevated uric acid level, Elevated uric acid level in blood, High blood uric acid level, Hyperuricaemia, Increased uric acid concentration, Increased uric acid level, Increased uric acid level in blood
Highest stage of its drugs: Approval, for 7 of its 34 drugs, from DailyMed, EMA Human Drugs, FDA, PMDA and TTD

Source Open Targets

Drugs34

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
FEBUXOSTAT	CHEMBL1164729	Small molecule	Approval	DailyMed, EMA Human Drugs, PMDA and TTD	34	28	28	Drugs and targets
ALLOPURINOL	CHEMBL1467	Small molecule	Approval	TTD	13	12	12	Drugs and targets
RASBURICASE	CHEMBL1201594	Enzyme	Approval	EMA Human Drugs, PMDA and TTD	12	9	9	Drugs and targets
DOTINURAD	CHEMBL4594446	Small molecule	Approval	PMDA	10	9	9	Drugs and targets
LESINURAD	CHEMBL2105720	Small molecule	Approval	FDA and TTD	5	2	2	Drugs and targets
TOPIROXOSTAT	CHEMBL1078685	Small molecule	Approval	PMDA	2	1	1	Drugs and targets
PROBENECID	CHEMBL897	Small molecule	Approval	TTD	1	0	0	Drugs and targets
PEGLOTICASE	CHEMBL1237025	Enzyme	Phase 3	ClinicalTrials.gov	5	5	4	Drugs and targets
TIGULIXOSTAT	CHEMBL3652780	Small molecule	Phase 3	ClinicalTrials.gov	3	3	3	Drugs and targets
BENZBROMARONE	CHEMBL388590	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets

1 to 10 of 34

See all 34 drugs

Targets33

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
SLC22A12	Solute carrier family 22 member 12	6	Solute carrier family 22 member 12 inhibitor	Approval	https://conductscience.org/library/genes/116085	Drugs and targets
XDH	Xanthine dehydrogenase/oxidase	3	Xanthine dehydrogenase inhibitor	Approval	https://conductscience.org/library/genes/7498	Drugs and targets
ADRA1A	Adrenergic receptor alpha-1	1	Adrenergic receptor alpha-1 antagonist	Phase 2/3	https://conductscience.org/library/genes/148	Drugs and targets
ADRA1B	Adrenergic receptor alpha-1	1	Adrenergic receptor alpha-1 antagonist	Phase 2/3	https://conductscience.org/library/genes/147	Drugs and targets
ADRA1D	Adrenergic receptor alpha-1	1	Adrenergic receptor alpha-1 antagonist	Phase 2/3	https://conductscience.org/library/genes/146	Drugs and targets
CACNA1C	Voltage-gated L-type calcium channel	1	Voltage-gated L-type calcium channel blocker	Phase 2/3	https://conductscience.org/library/genes/775	Drugs and targets
CACNA1D	Voltage-gated L-type calcium channel	1	Voltage-gated L-type calcium channel blocker	Phase 2/3	https://conductscience.org/library/genes/776	Drugs and targets
CACNA1F	Voltage-gated L-type calcium channel	1	Voltage-gated L-type calcium channel blocker	Phase 2/3	https://conductscience.org/library/genes/778	Drugs and targets
CACNA1S	Voltage-gated L-type calcium channel	1	Voltage-gated L-type calcium channel blocker	Phase 2/3	https://conductscience.org/library/genes/779	Drugs and targets
FKBP1A	Peptidyl-prolyl cis-trans isomerase FKBP1A	1	FK506-binding protein 1A inhibitor	Phase 2	https://conductscience.org/library/genes/2280	Drugs and targets

1 to 10 of 33

See all 33 targets

Trials74

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT01391325	Allopurinol Outcome Study	Phase 4	1,735	2014-06-17	Gout	ALLOPURINOL	Its record names the disease	ClinicalTrials.gov
NCT03990363	A Study of Verinurad and Allopurinol in Patients With Chronic Kidney Disease and Hyperuricaemia	Phase 2	861	2023-03-02	Chronic Kidney Disease	ALLOPURINOL, VERINURAD	Its record names the disease	ClinicalTrials.gov
NCT02082769	Safety and Efficacy of Oral Febuxostat in Subjects With Gout	Phase 3	504	2016-02-03	Gout	ALLOPURINOL, FEBUXOSTAT	Its record names the disease	ClinicalTrials.gov
NCT01078389	Effect of Febuxostat on Joint Damage in Hyperuricemic Subjects With Early Gout	Phase 2	314	2014-09-10	Joint Damage	FEBUXOSTAT	Its record names the disease	ClinicalTrials.gov
NCT00325195	Safety and Efficacy Study of PEG-uricase in the Treatment of Hyperuricemic Patients With Symptomatic Gout	Phase 3	225	2011-02-25	Gout	PEGLOTICASE	Its record names the disease	ClinicalTrials.gov
NCT02128490	Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout and Moderate Renal Impairment	Phase 2	189	2016-11-03	Gout, Moderate Renal Impairment	FEBUXOSTAT	Its record names the disease	ClinicalTrials.gov
NCT03934099	A Study to Assess Efficay and Safety of LC350189 Different Doses in Gout Patients With Hyperuricemia	Phase 2	156	2025-12-03	Gout, Hyperuricemia	TIGULIXOSTAT	Its record names the disease	ClinicalTrials.gov
NCT02959918	Multi-Dose Safety/Pharmacodynamic Study of SEL-212/SEL-037 in Subjects With Symptomatic Gout & Elevated Blood Uric Acid	Phase 2	152	2022-02-14	Gout Chronic, Hyperuricemia	PEGADRICASE, SIROLIMUS	Its record names the disease	ClinicalTrials.gov
NCT01496469	Effect of Febuxostat on Blood Pressure	Phase 2	121	2015-08-31	Hypertension	FEBUXOSTAT	Its record names the disease	ClinicalTrials.gov
NCT00174941	Long-Term Safety of Febuxostat in Subjects With Gout.	Phase 2	116	2009-07-16	Gout	FEBUXOSTAT	Its record names the disease	ClinicalTrials.gov

1 to 10 of 74

See all 74 trials

Comparisons in its trials8

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Febuxostat 40 mg or 80 mg vs Placebo: serious adverse events	13 of 157	11 of 157	314	NCT01078389	Trial comparisons
Allopurinol vs Placebo: deaths from any cause	0 of 99	0 of 99	198	NCT02038179	Trial comparisons
Allopurinol vs Placebo: serious adverse events	0 of 99	0 of 99	198	NCT02038179	Trial comparisons
Febuxostat 80 mg vs Placebo: serious adverse events	1 of 61	1 of 60	121	NCT01496469	Trial comparisons
Treatment Sequence A+B vs Treatment Sequence B+A: deaths from any cause	0 of 35	0 of 36	71	NCT03316131	Trial comparisons
Treatment Sequence A+B vs Treatment Sequence B+A: serious adverse events	0 of 35	0 of 36	71	NCT03316131	Trial comparisons
Verinurad 9 mg+Febuxostat 80 mg vs Placebo: deaths from any cause	0 of 32	0 of 28	60	NCT03118739	Trial comparisons
Verinurad 9 mg+Febuxostat 80 mg vs Placebo: serious adverse events	5 of 32	3 of 28	60	NCT03118739	Trial comparisons

Papers from its trials59

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
39835962	RESULT	1	PubMed
39300602	RESULT	1	PubMed
38468241	RESULT	1	PubMed
37993515	RESULT	1	PubMed
36388084	RESULT	1	PubMed
35342538	RESULT	1	PubMed
34907116	RESULT	1	PubMed
33399399	RESULT	1	PubMed
31870173	RESULT	1	PubMed
30085130	RESULT	1	PubMed

1 to 10 of 59

See all 59 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/EFO_0009104

GET https://conductscience.org/api/diseases/v1/EFO_0009104/drugs?page=2

API reference For AI assistants